Skip to content

诺沃库尔

US · NVCR #2889 按市值排名 上市于 2015
14.07 -0.34 -2.36%
实时 - 追踪5344个代码 - 心跳于43秒前 · 2026-10-16 19:30

✦ 量化财务健康度 计算方式说明

偏弱
  • 奥特曼 Z 值为0.69,低于1.8的"危险区"阈值。
  • 该模型对工业和制造业公司最为可靠,对银行、保险等金融类公司参考意义较弱。

营收 年度数据,近8年

最近年度同比+8.28%

利润率

毛利率
74.54%
营业利润率
-23.47%
净利率
-20.79%

关键比率与质量指标

奥特曼 Z 值低于约1.8提示财务困境风险,高于约3.0提示风险较低;该模型对工业和制造业公司最为可靠,对银行等金融类公司参考意义较弱。

利润表

项目 2018 2019 2020 2021 2022 2023 2024 2025
营收 248.07M351.32M494.37M535.03M537.84M509.34M605.22M655.35M
毛利润 168.02M262.71M387.87M420.15M422.97M381.06M468.04M488.47M
销售及管理费用 151.12M184.62M225.45M263.18M306.41M390.87M428.89M417.73M
研发费用 50.57M79.00M132.01M201.30M206.09M223.06M209.65M224.54M
营业利润 -33.67M-914.00K30.40M-44.33M-89.52M-232.87M-170.50M-153.80M
税前利润 -45.94M-8.82M18.10M-52.08M-81.85M-191.74M-131.16M-136.25M
税费 17.62M-1.59M-1.71M6.28M10.69M15.30M37.47M-23.00K
净利润 -63.56M-7.23M19.81M-58.35M-92.53M-207.04M-168.63M-136.23M
基本每股收益 -100-1-1-2-2-1
稀释每股收益 -0.69-0.070.18-0.56-0.88-1.95-1.56-1.22

资产负债表

项目 2018 2019 2020 2021 2022 2023 2024 2025
流动资产总额 321.37M439.95M999.44M1.07B1.11B1.03B1.11B646.73M
现金及短期投资 245.88M326.09M842.58M937.70M969.43M910.62M959.87M447.67M
存货 22.56M23.70M27.42M24.43M29.38M38.15M35.09M41.11M
总资产 339.79M479.45M1.05B1.14B1.19B1.15B1.24B804.33M
流动负债总额 64.56M86.31M113.61M142.60M158.78M179.12M756.39M223.23M
短期负债 ----------8.32M566.07M11.66M
长期负债 149.27M149.42M429.91M562.22M565.51M568.82M97.30M195.05M
总负债 227,534,000.00261,658,000.00575,457,000.00729,001,000.00750,478,000.00783,633,000.00880,605,000.00463,860,000.00
股东权益总额 112.26M217.79M476.53M410.49M441.17M362.50M360.18M340.47M
留存收益 -643.66M-650.89M-631.08M-685.93M-778.46M-985.50M-1.15B-1.29B

现金流量表

项目 2018 2019 2020 2021 2022 2023 2024 2025
经营活动现金流 -1.87M26.62M99.15M82.76M30.79M-73.34M-26.37M-49.03M
折旧与摊销 9.01M8.46M9.15M10.25M10.62M10.97M11.24M14.65M
自由现金流 -8.58M16.14M84.18M58.59M9.43M-100.43M-69.22M-75.68M
已派股息 ----------------
股票回购/发行 1.84M2.47M3.37M4.55M5.22M4.42M4.15M3.66M
期末现金余额 142.76M179.42M246.17M209.61M115.83M242.56M166.09M103.39M

回报与效率指标

项目 2018 2019 2020 2021 2022 2023 2024 2025
净资产收益率 -56.29-4.385.71-13.16-21.73-51.52-46.67-38.89
总资产收益率 -21.01-1.772.59-5.33-7.94-17.71-14.13-13.32
投入资本回报率 -23.530.124.82-5.92-9.80-22.17-13.89-16.18
5年平均净资产收益率 -59.08-47.99-34.05-23.26-17.97-17.02-25.47-34.39
息税前利润率 -13.081.397.23-9.09-14.60-36.99-19.96-18.19
自由现金流/营收 --4.5917.0310.951.75------
流动比率 4.985.108.807.537.005.781.462.90
速动比率 4.544.778.427.326.775.511.402.63
资产负债率 43.9334.1242.2250.4849.0352.7555.0730.88
长期负债权益比 132.9775.1093.22140.13132.44164.4832.5669.52
利息保障倍数 -2.410.362.02-14.14-23.55-56.77-11.68-7.00
营收复合年增长率(3年) 95.7261.8340.8229.2015.251.004.196.81
净利润复合年增长率(3年) ----------------
自由现金流复合年增长率(3年) ---------16.39------

营收构成 最近报告期

业务分部

Development, manufacture and commercialization of Tumor Treating Fields (TTFields) as treatment for100.00%

地区分部

United States58.84%
Germany12.12%
France11.63%
Other international markets8.68%
Japan5.77%
Greater China2.97%

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

诺沃库尔 讨论区 0 条评论

发表评论